Canaccord Genuity Maintains a 'Buy' on AVEO Pharmaceuticals (AVEO); Tivo Still Positioned Well in the Face of Decent Axitinib Data

Canaccord Genuity maintains a 'Buy' on AVEO Pharmaceuticals (NASDAQ: AVEO), PT $28.

Canaccord analyst, Dr. George Farmer, said, "Following presentation of Pfizer’s (NYSE: PFE) Phase III AXIS trial at ASCO, we remain positive on AVEO shares going into top-line data release from the Phase III TIVO-1 trial to support FDA registration of tivozanib as a treatment for metastatic renal cell carcinoma (RCC)."

For more ratings news on AVEO Pharmaceuticals click here and for the rating history of AVEO Pharmaceuticals click here.

Shares of AVEO Pharmaceuticals closed at $18.99 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Barclays Downgrades Renault SA (RNO:FP) (RNSDF) to Equalweight
• Marti Technologies (MRT) PT Raised to $6 at Benchmark on Stronger Growth, Improved Earnings Visibility
• SentinelOne Inc (S) PT Raised to $26 at Cantor Fitzgerald Following Strong Q2 Checks